Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (9109)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Nov 21, 2014 (publication date) through Apr 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Andersen NN, Jess T. Risk of infections associated with biological treatment in inflammatory bowel disease. World J Gastroenterol 2014; 20(43): 16014-16019 [PMID: 25473153 DOI: 10.3748/wjg.v20.i43.16014] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v20/i43/16014.htm |
| Number | Citing Articles |
| 1 |
Mohamed A Abd El Aziz, Solafah Abdalla, Giacomo Calini, Hamadelneel Saeed, Luca Stocchi, Amit Merchea, Dorin T Colibaseanu, Sherief Shawki, David W Larson. Postoperative Safety Profile of Minimally Invasive Ileocolonic Resections for Crohn’s Disease in the Era of Biologic Therapy. Journal of Crohn's and Colitis 2022; 16(7): 1079 doi: 10.1093/ecco-jcc/jjac012
|
| 2 |
Alok Kumar Mantri, Priti Meena, Amarender Singh Puri, Ajay Kumar, Sanjeev Sachdeva, Siddharth Srivastava, K. Arivarasan, Shivakumar Varakanahali, Jos R. Lapa e Silva. Comparison of Interferon-Gamma Release Assay and Tuberculin Skin Test for the Screening of Latent Tuberculosis in Inflammatory Bowel Disease Patients: Indian Scenario. Tuberculosis Research and Treatment 2021; 2021: 1 doi: 10.1155/2021/6682840
|
| 3 |
Raja Atreya, Markus F. Neurath. Predicting Therapeutic Response by in vivo Molecular Imaging in Inflammatory Bowel Diseases. Digestive Diseases 2016; 34(5): 552 doi: 10.1159/000445262
|
| 4 |
Peter Waterland, Thanos Athanasiou, Heena Patel. Post-operative abdominal complications in Crohn’s disease in the biological era: Systematic review and meta-analysis. World Journal of Gastrointestinal Surgery 2016; 8(3): 274-283 doi: 10.4240/wjgs.v8.i3.274
|
| 5 |
Diego Orsini, Alessandra Narcisi, Annalisa Arcese, Antonio Costanzo. Long-term safety of etanercept in psoriasis: Retrospective study focused on infections. Journal of International Medical Research 2016; 44(1_suppl): 58 doi: 10.1177/0300060515593252
|
| 6 |
Siddharth Singh, Nynne Nyboe Andersen, Mikael Andersson, Edward V. Loftus, Tine Jess. Comparison of Infliximab and Adalimumab in Biologic-Naive Patients With Ulcerative Colitis: A Nationwide Danish Cohort Study. Clinical Gastroenterology and Hepatology 2017; 15(8): 1218 doi: 10.1016/j.cgh.2016.11.024
|
| 7 |
Dan Turner, Frank M. Ruemmele, Esther Orlanski‐Meyer, Anne M. Griffiths, Javier Martin de Carpi, Jiri Bronsky, Gabor Veres, Marina Aloi, Caterina Strisciuglio, Christian P. Braegger, Amit Assa, Claudio Romano, Séamus Hussey, Michael Stanton, Mikko Pakarinen, Lissy de Ridder, Konstantinos Katsanos, Nick Croft, Victor Navas‐López, David C. Wilson, Sally Lawrence, Richard K. Russell. Management of Paediatric Ulcerative Colitis, Part 1. Journal of Pediatric Gastroenterology and Nutrition 2018; 67(2): 257 doi: 10.1097/MPG.0000000000002035
|
| 8 |
Paula Sousa, Matthieu Allez. Complications of biologics in inflammatory bowel disease. Current Opinion in Gastroenterology 2015; 31(4): 296 doi: 10.1097/MOG.0000000000000191
|
| 9 |
Paweł Moćko, Paweł Kawalec, Andrzej Pilc. Safety Profile of Biologic Drugs in the Treatment of Inflammatory Bowel Diseases: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials. Clinical Drug Investigation 2017; 37(1): 25 doi: 10.1007/s40261-016-0459-y
|
| 10 |
Jason Reinglas, Lorant Gonczi, Zsuzsanna Kurt, Talat Bessissow, Peter L Lakatos. Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases. World Journal of Gastroenterology 2018; 24(32): 3567-3582 doi: 10.3748/wjg.v24.i32.3567
|
| 11 |
Taku Kobayashi, Satoshi Motoya, Shiro Nakamura, Takayuki Yamamoto, Masakazu Nagahori, Shinji Tanaka, Tadakazu Hisamatsu, Fumihito Hirai, Hiroshi Nakase, Kenji Watanabe, Takayuki Matsumoto, Masanori Tanaka, Takayuki Abe, Yasuo Suzuki, Mamoru Watanabe, Toshifumi Hibi, Shingo Kato, Atsushi Maemoto, Minoru Matsuura, Ryosuke Sakemi, Makoto Sasaki, Tomoyuki Tsujikawa, Motohiro Esaki, Norimasa Fukata, Kazuya Kitamura, Sakiko Hiraoka, Ryota Hokari, Shunji Ishihara, Tsutomu Mizoshita, Yuji Naito, Fumio Omata, Masayuki Saruta, Takuya Yoshino. Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial. The Lancet Gastroenterology & Hepatology 2021; 6(6): 429 doi: 10.1016/S2468-1253(21)00062-5
|
| 12 |
Paula Dávila-Seijo, Esteban Dauden, M.A. Descalzo, Gregorio Carretero, José-Manuel Carrascosa, Francisco Vanaclocha, Francisco-José Gómez-García, Pablo De la Cueva-Dobao, Enrique Herrera-Ceballos, Isabel Belinchón, José-Luis López-Estebaranz, Merce Alsina, José-Luis Sánchez-Carazo, Marta Ferrán, Rosa Torrado, Carlos Ferrandiz, Raquel Rivera, Mar Llamas, Rafael Jiménez-Puya, Ignacio García-Doval, Beatriz Pérez Zafrilla, Carlos Muñoz-Santos, Victoria Mendiola-Fernández, Cristina Sánchez Roldán, Diana Ruiz-Genao, Begoña Echeverría, Sagrario Galiano Mejías. Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry. Journal of Investigative Dermatology 2017; 137(2): 313 doi: 10.1016/j.jid.2016.08.034
|
| 13 |
Máire A. Conrad, Judith R. Kelsen. The Treatment of Pediatric Inflammatory Bowel Disease with Biologic Therapies. Current Gastroenterology Reports 2020; 22(8) doi: 10.1007/s11894-020-00773-3
|
| 14 |
Pooja Mehta, Zhaoxing Pan, Glenn T. Furuta, David Yonghyuk Kim, Edwin F. de Zoeten. Parent Perspectives on Exclusive Enteral Nutrition for the Treatment of Pediatric Crohn Disease. Journal of Pediatric Gastroenterology and Nutrition 2020; 71(6): 744 doi: 10.1097/MPG.0000000000002847
|
| 15 |
Alice Capogrosso Sansone, Stefania Mantarro, Marco Tuccori, Elisa Ruggiero, Sabrina Montagnani, Irma Convertino, Alessandra Marino, Matteo Fornai, Luca Antonioli, Tiberio Corona, Danila Garibaldi, Corrado Blandizzi. Safety Profile of Certolizumab Pegol in Patients with Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis. Drug Safety 2015; 38(10): 869 doi: 10.1007/s40264-015-0336-2
|
| 16 |
C. Monasterio, W. Kreisel, P. Hasselblatt. Schwere Lymphozytopenie bei Patientin mit Morbus Crohn. Der Internist 2018; 59(8): 857 doi: 10.1007/s00108-017-0363-4
|
| 17 |
Kailing Wang, Youwen Zhu, Kun Liu, Hong Zhu, Miao Ouyang. Adverse events of biologic or small molecule therapies in clinical trials for inflammatory bowel disease: A systematic review and meta-analysis. Heliyon 2024; 10(4): e25357 doi: 10.1016/j.heliyon.2024.e25357
|
| 18 |
Ju Yeon Ryoo, Hye-Jin Yang, Eunhee Ji, Bong Kyu Yoo. Meta-analysis of the Efficacy and Safety of Secukinumab for the Treatment of Plaque Psoriasis. Annals of Pharmacotherapy 2016; 50(5): 341 doi: 10.1177/1060028015626545
|
| 19 |
Scott Healey, Waseem Said, Faisal Fayyaz, Andrew Bell. First report of paracoccidioidomycosis reactivation as a complication of immunosuppressive therapy for acute severe colitis in a caving enthusiast. BMJ Case Reports 2020; 13(7): e234125 doi: 10.1136/bcr-2019-234125
|
| 20 |
D. Devadason, K. Jones, A. Rodrigues. The use of biologicals in paediatric onset inflammatory bowel disease. Paediatrics and Child Health 2016; 26(10): 441 doi: 10.1016/j.paed.2016.07.004
|
| 21 |
Fynn M. Hansen, Maria C. Tanzer, Franziska Brüning, Isabell Bludau, Che Stafford, Brenda A. Schulman, Maria S. Robles, Ozge Karayel, Matthias Mann. Data-independent acquisition method for ubiquitinome analysis reveals regulation of circadian biology. Nature Communications 2021; 12(1) doi: 10.1038/s41467-020-20509-1
|
| 22 |
Tero Ylisaukko-oja, Jaakko Aaltonen, Heikki Nuutinen, Timo Blomster, Airi Jussila, Markku Pajala, Kimmo Salminen, Veikko Moilanen, Kalle Hakala, Mikko Kellokumpu, Kari Toljamo, Henna Rautiainen, Juha Kuisma, Markku Peräaho, Pauliina Molander, Jouni Silvennoinen, Ville Liukkonen, Hans Henricson, Jyrki Tillonen, Mirva Esterinen, Christian Nielsen, Eija Hirsi, Margus Lääne, Ulla-Maija Suhonen, Ilkka Vihriälä, Petri Mäkelä, Mika Puhto, Jari Punkkinen, Hannu Sulonen, Sauli Herrala, Jari Jokelainen, Klaus Tamminen, Taina Sipponen. High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab – a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO). Scandinavian Journal of Gastroenterology 2018; 53(2): 158 doi: 10.1080/00365521.2017.1416160
|
| 23 |
Andreas Muehler, Jason R Slizgi, Hella Kohlhof, Manfred Groeppel, Evelyn Peelen, Daniel Vitt. Clinical relevance of intestinal barrier dysfunction in common gastrointestinal diseases. World Journal of Gastrointestinal Pathophysiology 2020; 11(6): 114-130 doi: 10.4291/wjgp.v11.i6.114
|
| 24 |
Sandro da Costa FERREIRA, Rogério Serafim PARRA, Marley Ribeiro FEITOSA, Omar FERES, Rodrigo de Carvalho SANTANA, Luiz Ernesto de Almeida TRONCON. PREVALENCE AND PREDICTIVE FACTORS ASSOCIATED WITH POSITIVITY OF SARS-COV-2 SEROLOGICAL MARKERS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AT AN IBD REFERRAL CENTER. Arquivos de Gastroenterologia 2022; 59(2): 170 doi: 10.1590/s0004-2803.202202000-32
|
| 25 |
Soo-Young Na, Chang Hwan Choi, Eun Mi Song, Ki Bae Bang, Sang Hyoung Park, Eun Soo Kim, Jae Jun Park, Bora Keum, Chang Kyun Lee, Bo-In Lee, Seung-Bum Ryoo, Seong-Joon Koh, Miyoung Choi, Joo Sung Kim. Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis. Intestinal Research 2023; 21(1): 61 doi: 10.5217/ir.2022.00007
|
| 26 |
Shengjie Li, Aoxiang Zhuge, Hui Chen, Shengyi Han, Jian Shen, Kaicen Wang, Jiafeng Xia, He Xia, Shiman Jiang, Youhe Wu, Lanjuan Li. Sedanolide alleviates DSS-induced colitis by modulating the intestinal FXR-SMPD3 pathway in mice. Journal of Advanced Research 2024; doi: 10.1016/j.jare.2024.03.026
|
| 27 |
MH Lee, CH Ng, YH Chin, M Muthiah, FJ Foo, CS Chong. Incidence of SARS‐CoV‐2 infection in inflammatory bowel disease. Journal of Gastroenterology and Hepatology 2020; 35(11): 2021 doi: 10.1111/jgh.15191
|
| 28 |
Donovan G. Kearns, Shelley Uppal, Vipawee S. Chat, Jashin J. Wu. Use of systemic therapies for psoriasis in the COVID-19 era. Journal of Dermatological Treatment 2022; 33(2): 622 doi: 10.1080/09546634.2020.1775774
|
| 29 |
Gerd Horneff, Marieke M.B. Seyger, Dilek Arikan, Jasmina Kalabic, Jaclyn K. Anderson, Andreas Lazar, David A. Williams, Chen Wang, Rita Tarzynski-Potempa, Jeffrey S. Hyams. Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn's Disease. The Journal of Pediatrics 2018; 201: 166 doi: 10.1016/j.jpeds.2018.05.042
|
| 30 |
Jia-Mei Rong, Juan Luo, Qi Huang, Ying-Lei Miao. Individualized selection of biological agents in treatment of inflammatory bowel disease. World Chinese Journal of Digestology 2021; 29(15): 893 doi: 10.11569/wcjd.v29.i15.893
|
| 31 |
Immunology and the Skin: A Clinical Conversation with Alan Dattner, MD, and Robert Rountree, MD. Alternative and Complementary Therapies 2016; 22(6): 231 doi: 10.1089/act.2016.29079.amd
|
| 32 |
Ting Liu, Zunxi Ning, Pengyu Liu, Huiyuan Gao. Cassane diterpenoid ameliorates dextran sulfate sodium-induced experimental colitis by regulating gut microbiota and suppressing tryptophan metabolism. Frontiers in Immunology 2023; 13 doi: 10.3389/fimmu.2022.1045901
|
| 33 |
Gihun Jeong, Jihye You. A Case of 1-Month Fever Caused by CMV Infection in a Patient With MIS-C Treated With IVIG, Infliximab, and High-Dose Methylprednisolone. Pediatric Infection & Vaccine 2024; 31 doi: 10.14776/piv.2024.31.e12
|
| 34 |
Jung Yoon Jang, Eunok Im, Nam Deuk Kim. Therapeutic Potential of Bioactive Components from Scutellaria baicalensis Georgi in Inflammatory Bowel Disease and Colorectal Cancer: A Review. International Journal of Molecular Sciences 2023; 24(3): 1954 doi: 10.3390/ijms24031954
|
| 35 |
Soo-Young Na, Won Moon. Perspectives on Current and Novel Treatments for Inflammatory Bowel Disease. Gut and Liver 2019; 13(6): 604 doi: 10.5009/gnl19019
|
| 36 |
Lieven Pouillon, Peter Bossuyt, Laurent Peyrin-Biroulet. Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease. Expert Opinion on Biological Therapy 2016; 16(10): 1277 doi: 10.1080/14712598.2016.1203897
|
| 37 |
Andrew Tinsley, Seyedehsan Navabi, Emmanuelle D Williams, Guodong Liu, Lan Kong, Matthew D Coates, Kofi Clarke. Increased Risk of Influenza and Influenza-Related Complications Among 140,480 Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2019; 25(2): 369 doi: 10.1093/ibd/izy243
|
| 38 |
S. Riestra, C. Taxonera, D. Carpio, A. López-San Román, J.P. Gisbert, E. Domènech. Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre el cribado y tratamiento de la tuberculosis latente en pacientes con enfermedad inflamatoria intestinal. Enfermedad Inflamatoria Intestinal al Día 2015; 14(3): 109 doi: 10.1016/j.eii.2015.09.001
|
| 39 |
José M. Ferro, Miguel Oliveira Santos. Neurology of inflammatory bowel disease. Journal of the Neurological Sciences 2021; 424: 117426 doi: 10.1016/j.jns.2021.117426
|
| 40 |
Andrew Leber, Raquel Hontecillas, Victoria Zoccoli-Rodriguez, Jean-Frederic Colombel, Jyoti Chauhan, Marion Ehrich, Nicholas Farinola, Josep Bassaganya-Riera. The Safety, Tolerability, and Pharmacokinetics Profile of BT-11, an Oral, Gut-Restricted Lanthionine Synthetase C-Like 2 Agonist Investigational New Drug for Inflammatory Bowel Disease: A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Trial. Inflammatory Bowel Diseases 2019; doi: 10.1093/ibd/izz094
|
| 41 |
Ying-Ying Chen, Rui-Yan Li, Mei-Jing Shi, Ya-Xing Zhao, Yan Yan, Xin-Xin Xu, Miao Zhang, Xiao-Tong Zhao, Yu-Bin Zhang. Demethyleneberberine alleviates inflammatory bowel disease in mice through regulating NF-κB signaling and T-helper cell homeostasis. Inflammation Research 2017; 66(2): 187 doi: 10.1007/s00011-016-1005-3
|
| 42 |
Mauro Perretti, Clara Di Filippo, Michele D’Amico, Jesmond Dalli, John Wallace. Characterizing the anti-inflammatory and tissue protective actions of a novel Annexin A1 peptide. PLOS ONE 2017; 12(4): e0175786 doi: 10.1371/journal.pone.0175786
|
| 43 |
Joshua S. Davis, David Ferreira, Emma Paige, Craig Gedye, Michael Boyle. Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies. Clinical Microbiology Reviews 2020; 33(3) doi: 10.1128/CMR.00035-19
|
| 44 |
Patrizia Alvisi, Valeria Dipasquale, Arrigo Barabino, Stefano Martellossi, Erasmo Miele, Paolo Lionetti, Giuliano Lombardi, Salvatore Cucchiara, Giuliano Torre, Claudio Romano. Infections and malignancies risks related to TNF-α-blocking agents in pediatric inflammatory bowel diseases. Expert Review of Gastroenterology & Hepatology 2019; 13(10): 957 doi: 10.1080/17474124.2019.1663173
|
| 45 |
Carl Eriksson, Jan Marsal, Daniel Bergemalm, Lina Vigren, Jan Björk, Michael Eberhardson, Pontus Karling, Charlotte Söderman, Pär Myrelid, Yang Cao, Daniel Sjöberg, Mari Thörn, Per Karlén, Erik Hertervig, Hans Strid, Jonas F. Ludvigsson, Sven Almer, Jonas Halfvarson. Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG). Scandinavian Journal of Gastroenterology 2017; 52(6-7): 722 doi: 10.1080/00365521.2017.1304987
|